FDA cell-therapy oversight faces 'modernization'—safety or speed?
S. 4885 — Shandra Eisenga Human Cell and Tissue Product Safety Act · Filed by Gary Peters (D-MI) · 1 cosponsor · Introduced Jun 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the HHS Secretary to run a public education campaign about cell and tissue transplants, establishes civil penalties (up to $20,000 per violation, $10M cap) for companies that violate FDA regulations on human cell and tissue products, and directs the FDA to publish information about its oversight activities, hold stakeholder workshops, and report to Congress on modernizing the regulatory framework for these products. The bill is named after Shandra Eisenga, suggesting a victim-protection or safety motivation.
Why we flagged it
The bill's headline is patient education and enforcement, but its operative mechanism is a comprehensive regulatory review aimed at 'streamlining' oversight of cell and tissue products—a classic deregulatory posture wrapped in safety language. The civil penalties are real but capped; the transparency measures are real but paired with a mandate to reduce 'regulatory burden.'
What the text implies
- The $10M civil-penalty cap may be insufficient to deter violations by large pharmaceutical and biotech firms, especially if violations involve high-value products or repeated breaches.
- The mandate to consider 'regulatory burden' and 'access' in modernizing oversight could justify loosening standards for 'minimal manipulation' and 'homologous use'—terms that define which cell/tissue products require full FDA approval vs. lighter oversight.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers (BMY, PFE, JNJ); biotech firms developing cell and tissue therapies; tissue-bank operators and establishments